Recent Updates
Recently added Catalysts
AGEN Negative Sentiment Score: 25/100

Agenus Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before November 5, 2024 to Discuss Your Rights – AGEN

Key Takeaway: Agenus Inc. is currently involved in a class action securities lawsuit filed by Levi & Korsinsky, LLP on behalf of investors who suffered losses due to alleged securities fraud. This legal action concerns claims that the company's immuno-oncology products, botensilimab and balstilimab, were inaccurately portrayed as more effective than they are. Investors have until November 5, 2024, to involve themselves in the case and potentially recover damages. The allegations suggest that Agenus' prior statements regarding its products' clinical and commercial prospects were misleading.

Market Sentiment Analysis

CONCERNS & RISKS

  • Agenus is facing a class action lawsuit alleging securities fraud.
  • The lawsuit claims that the company's therapeutic products were less effective than publicly stated.
  • Public statements from Agenus were deemed materially false and misleading.
  • Investors may suffer financial losses as a result of the alleged deception.

Full Press Release Details

NEW YORK, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Agenus Inc. ("Agenus" or the "Company") (NASDAQ: AGEN) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Agenus investors who were adversely affected by alleged securities fraud between January 23, 2023 and July 17, 2024. Follow the link below to get more information and be contacted by a member of our team:
AGEN investors may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) the combination therapy of their immuno-oncology products, botensilimab and balstilimab was less effective than the defendants had led investors to believe; (ii) accordingly, botensilimab and balstilimab’s clinical results, as well as their regulatory and commercial prospects, were overstated; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.
WHAT'S NEXT? If you suffered a loss in Agenus during the relevant time frame, you have until November 5, 2024 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.
WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
33 Whitehall Street, 17th Floor

Tags

Frequently Asked Questions

What is the class action lawsuit against Agenus Inc. about?

The lawsuit concerns alleged securities fraud affecting Agenus investors from January 23, 2023, to July 17, 2024.

What were the allegations made in the complaint?

The complaint claims false statements about the efficacy of Agenus's combination therapy and exaggerated clinical and commercial prospects.

Is there a cost to participate in the lawsuit?

No, class members may be entitled to compensation without any out-of-pocket costs.

What should affected investors do next?

Affected investors must request to be appointed as lead plaintiff by November 5, 2024.

Who can investors contact regarding the lawsuit?

Investors can contact Joseph E. Levi at jlevi@levikorsinsky.com or call (212) 363-7500.

Last updated: Sep 19, 2024